Trial · NCT02312882
Tofacitinib for the Treatment of Alopecia Areata and Its Variants
NCT02312882, Not applicable, Completed, Stanford University; results first posted 2017-11-06
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Tofacitinib for the Treatment of Alopecia Areata and Its Variants. Trials, record NCT02312882. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02312882
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Tofacitinib for the Treatment of Alopecia Areata and Its Variants
- NCT number
- NCT02312882
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 40 participants, actual
- Lead sponsor
- Stanford University
- Conditions
- Alopecia Areata, Alopecia Totalis, Alopecia Universalis
- Interventions
- Tofacitinib
- First posted
- 2014-12-09
- Last updated
- 2017-11-06
- Results first posted
- 2017-11-06
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percent Change in Severity of Alopecia Tool (SALT) Score | 0 and 3 months | SALT score range is from 0 (no hair loss) to 100 (100% hair loss). Positive percent change from baseline corresponds to reduction in SALT score. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percent Change in Severity of Alopecia Tool (SALT) Score | 0 and 3 months | Percent change | MEDIAN |
Source ClinicalTrials.gov
Results by group1
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Change in Severity of Alopecia Tool (SALT) Score | Treatment Arm | 30.7 | Full Range 0 to 87.4 | Percent change |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Tofacitinib | 40 | |
| Overall Study | COMPLETED | Tofacitinib | 36 | |
| Overall Study | NOT COMPLETED | Tofacitinib | 4 |
Source ClinicalTrials.gov
Adverse events16
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal pain | Gastrointestinal disorders | Treatment Arm | 2 | 40 | |
| other | Acne | Skin and subcutaneous tissue disorders | Treatment Arm | 2 | 40 | |
| other | Conjunctivitis | Eye disorders | Treatment Arm | 1 | 40 | |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Treatment Arm | 1 | 40 | |
| other | Diarrhoea | Gastrointestinal disorders | Treatment Arm | 2 | 40 | |
| other | Dry eyes | Eye disorders | Treatment Arm | 1 | 40 | |
| other | Fatigue | General disorders | Treatment Arm | 2 | 40 | |
| other | Folliculitis | Skin and subcutaneous tissue disorders | Treatment Arm | 1 | 40 | |
| other | Headache | Nervous system disorders | Treatment Arm | 2 | 40 | |
| other | Hot flashes | Endocrine disorders | Treatment Arm | 1 | 40 |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Treatment Arm | ||
| Total, other adverse events | Treatment Arm | 18 | 40 |
| Total, serious adverse events | Treatment Arm | 0 | 40 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 27699252 | RESULT |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02312882
GET https://conductscience.org/api/trials/v1/NCT02312882/registered